Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01449565 · ClinicalTrials.gov registry record · Phase 2
Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)
A Phase 2 study of Amphetamine-Related Disorders, sponsored by San Francisco Department of Public Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT01449565 is a Phase 2 study of Amphetamine-Related Disorders that has completed, run by San Francisco Department of Public Health. The registered enrollment target is 100 participants, above the 72-participant average among 5 other Amphetamine-Related Disorders trials with a reported enrollment target (39% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01449565, a Phase 2 study of Amphetamine-Related Disorders, has completed, sponsored by San Francisco Department of Public Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Extended-release naltrexone (XR-NTX, VIVITROL) is an FDA-approved medication with efficacy in treating alcohol dependence and prevention of relapse to opioid dependence. It has shown promise in reducing relapse to amphetamine use among amphetamine-dependent, yet currently amphetamine-abstinent heterosexuals. The investigators will expand upon this promising work to determine whether monthly intramuscular injections of naltrexone will reduce methamphetamine (meth) use among actively using, meth-dependent men who have sex with men (MSM) in this double-blind randomized controlled trial of extended-release naltrexone versus placebo. The investigators will focus on MSM because of the disproportionate and intertwining epidemics of meth use and HIV in this population.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Naltrexone
Study Locations (1)
California
- Substance Use Research Unit - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2012-09 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01449565
The ClinicalTrials.gov registry entry for NCT01449565 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 72-participant average among 5 other Amphetamine-Related Disorders trials with a reported enrollment target (39% higher). The listed sponsor is San Francisco Department of Public Health, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amphetamine-Related Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01449565 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01449565 about?
NCT01449565 is a clinical study titled "Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)". Extended-release naltrexone (XR-NTX, VIVITROL) is an FDA-approved medication with efficacy in treating alcohol dependence and prevention of relapse to opioid dependence. It has shown promise in reducing relapse to amphetamine use among amphetamine-dependent, yet currently amphetamine-abstinent heter...
What is the current status of trial NCT01449565?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2012-09. Estimated completion is 2016-03.
What conditions does trial NCT01449565 study?
This clinical trial studies the following conditions: Amphetamine-Related Disorders.
What interventions are being tested in trial NCT01449565?
The interventions under investigation include: Placebo (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT01449565?
This trial is sponsored by San Francisco Department of Public Health, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01449565 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amphetamine-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men
COMPLETED · Phase 2
-
Bupropion for the Treatment of Methamphetamine Dependence - 1
COMPLETED · Phase 2
-
Tyrosine for Methamphetamine Dependence - 1
COMPLETED · Phase 2
-
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
RECRUITING · Phase 1
-
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.